Protalix to present its biodefense agent at BARDA event

Biopharmaceutical company Protalix BioTherapeutics, Inc., will make an oral presentation at the Biomedical Advanced Research and Development Authority Industry Day on PRX-105, a compound that can be used as a biodefense agent against nerve gas.

The company's presentation is called "PRX-105: A Novel Biological Countermeasure for Nerve Agents" and it includes both preclinical and Phase I data. The preclinical studies have shown PRX-105 to successfully protect animals exposed to organophosphate nerve gas. The Phase I clinical trial established pharmacokinetics of the protein and showed that a single dose given intravenously was safe and well tolerated.

PRX-105 is a plant cell expressed pegylated recombinant human acetylcholinesterase that is in development for multiple prophylactic and therapeutic indications. Along with its biodefense capabilities, it may also be used in an organophosphate-based pesticide treatment program.

The BARDA Industry Day, occuring in conjunction with the U.S. Department of Health and Human Services 5th Annual Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop, runs from January 10 through January 12, 2011, in Washington D.C.

The presentation will be given on January 12. The BARDA Industry day includes over 40 oral presentations that highlight novel medical countermeasure research.

Protalix is a biopharmaceutical company that is focused on developing and commercializing recombinant therapeutic proteins through its proprietary cell-based expression system.